While FDA does not limit compounding to drug shortages and we believe there are paths to continue offering access to certain compounded GLP-1s after the shortage ends, we cannot guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all, due to a variety of factors outside our control, including supply chain, intellectual property, regulatory and resource allocation matters.) On October 2, 2024, this risk materialized when FDA announced on its website that Lilly had resolved the tirzepatide shortage, meaning that companies making and distributing compounded copies needed to stop in their tracks, regardless of ongoing patient care
According to the Washington Post, research shows that some people respond more slowly than others, and several factors can affect how well these medications work
You shouldnt have to read a long list of drugs to find the information you need, these platforms generally make it easy to search for a specific drug to see if the plan you're researching covers it
What MeAgain tracks in one GLP-1 app MeAgain keeps the everyday pieces of the GLP-1 journey together: shots or pills, dose history, injection sites, food, protein, fiber, water, side effects, weight, progress photos, the medication graph, and Capy